Overview of the DESTINY-Breast12 Study

Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand treatment options for this subgroup.

EP: 1.Overview of the DESTINY-Breast06 Study

Now Viewing

EP: 2.Overview of the DESTINY-Breast12 Study

EP: 3.Overview of the PATINA Study

Recent Videos